Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104190-104190
Open Access | Times Cited: 25

Showing 25 citing articles:

Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials
Wenjing Zhang, Zhanpeng Liang, Yurong Zhao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy
Jianzhen Shan, Zhen Liu, Songan Chen, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
Daniele Marinelli, A. Nuccio, Alessandro Di Federico, et al.
Journal of Thoracic Oncology (2024)
Closed Access | Times Cited: 4
Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
Qiong Zhang, Jia Duan, Yuanmei Zhang, et al.
Systematic Reviews (2025) Vol. 14, Iss. 1
Open Access
Challenges and opportunities in single-domain antibody-based tumor immunotherapy
Xiaozhi Xi, Guo Shu-hua, Yuchao Gu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189284-189284
Closed Access
Systemic Immune-Inflammation Index as a Predictor of Survival in Non-Small Cell Lung Cancer Patients Undergoing Immune Checkpoint Inhibition: A Systematic Review and Meta-Analysis
Ye Zhang, Yeye Chen, Chao Guo, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104669-104669
Closed Access
BRAF mutation and neoadjuvant chemo-immunotherapy, is it worthwhile?
Filippo Tommaso Gallina, Fabiana Letizia Cecere, Serenella Bergomi, et al.
Lung Cancer (2025), pp. 108514-108514
Closed Access
Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions
Arun Rajan, Alisa K. Sivapiromrat, Meredith J. McAdams
Cancers (2024) Vol. 16, Iss. 7, pp. 1369-1369
Open Access | Times Cited: 3
Surgically Resectable Non-Small Cell Lung Cancer: A Contemporary Approach
Marie-Frédérique D'Amours, Florence T.H. Wu, Olivia Theisen-Lauk, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 2, pp. 2400332-2400332
Open Access | Times Cited: 3
Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A Systematic Review and Meta-Analysis of Randomised Trials
Akshay J. Patel, Hanan Hemead, Jacie Law, et al.
European Journal of Cancer (2024) Vol. 214, pp. 115118-115118
Closed Access | Times Cited: 2
Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice
Xiaojie Huang, Guanchao Pang, Zhirong Mao, et al.
The Clinical Respiratory Journal (2024) Vol. 18, Iss. 5
Open Access | Times Cited: 1
Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis
Han Yue-Lin, Xiangtian Xiao, Tingting Qin, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access | Times Cited: 1
Systematic mediastinal staging in non‐small cell lung cancer: Filling in the guideline evidence gap
Daniel P. Steinfort
Respirology (2023) Vol. 29, Iss. 2, pp. 89-91
Open Access | Times Cited: 2
Neutrophil-to-Lymphocyte Ratio and Risk of Nodal Metastasis in Early-Stage Lung Adenocarcinoma: A Brief Report From a Multicentric Analysis
Filippo Tommaso Gallina, Marco Chiappetta, Riccardo Tajè, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 4, pp. e196-e200.e1
Closed Access
The Highest Mediastinal Lymph Node: Real or Faint Pillars of Hercules
Vincenzo Ambrogi, Alexandro Patirelis, Riccardo Tajè
Annals of Surgical Oncology (2024) Vol. 31, Iss. 8, pp. 4845-4846
Open Access
Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC
Filippo Tommaso Gallina, Vittoria Balzano, Nicla Porciello, et al.
Lung Cancer (2024) Vol. 194, pp. 107900-107900
Closed Access
Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC
Danielle Brazel, Misako Nagasaka
Med (2024) Vol. 5, Iss. 8, pp. 852-855
Closed Access
Tislelizumab synergizes with surgery to augment the survival benefit in stage II-III non-small cell lung cancer
Xuhua Huang, Linhai Zhu, Jia-Cong Liu, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
What do we know about the role of neoadjuvant targeted therapy in early-stage EGFR-mutant and ALK-fused non-small cell lung cancer?—a narrative review of the current literature
Marcel Kemper, Sandra Elges, Peter Kies, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 10, pp. 2813-2827
Open Access
The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer
M. Mayenga, Ana Rita Pedroso, Marion Ferreira, et al.
Breathe (2024) Vol. 20, Iss. 3, pp. 240044-240044
Open Access
Predictive and prognostic factors in patients with Anaplastic Lymphoma Kinase: rearranged early-stage lung adenocarcinoma
Filippo Tommaso Gallina, Fabiana Letizia Cecere, Riccardo Tajè, et al.
European Journal of Cardio-Thoracic Surgery (2024) Vol. 66, Iss. 5
Closed Access
Global trends and research hotspots in perioperative management of lung cancer: a bibliometric analysis from 2004 to 2024
Qinling Jiang, Zhiqiang Wei, Pingping Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
The oncogenic role and prognostic value of PXDN in human stomach adenocarcinoma
Yuan Tian, Shenghui Qiu, Yang Song, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
The Oncogenic Role and Prognostic Value of PXDN in Human Stomach Adenocarcinoma
Yuan Tian, Shenghui Qiu, Yang Song, et al.
Research Square (Research Square) (2023)
Open Access
Recommendations for the diagnosis, monitoring, and treatment of early-stage non-small cell lung cancer in Colombia
Diego Hernando Pardo, Lucía Viola, Jairo Zuluaga, et al.
Medicina (2023) Vol. 45, Iss. 4, pp. 767-804
Open Access
Page 1

Scroll to top